Molecular Partners AG
NASDAQ:MOLNBiotechnology
+$0.03 today
- Market cap
- $100.28M
- Beta
- 0.71
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.55
Volume 0.00M
Average 0.00M
MOLN Common Stock Issued
Cash raised by issuing new shares.
Molecular Partners AGNASDAQ: MOLN
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued growth accelerates
Q1 FY2026 common stock issued of CHF 8.18K rose 717.8% year over year, ahead of the +82.5% change in trailing-twelve-month common stock issued. Sequentially, it rose 1106.8% from the prior quarter. Over 3 fiscal years it compounded at -36.8% a year.
Context
- Common stock issued increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +717.8% holds above the trailing-twelve-month pace of +82.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
CHF · from the cash flow
- Latest · FY2025
- 63K CHF
- Year-over-year change
- -99.6%
- 4-year CAGR
- -81.3%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 63K | -99.6% |
| FY2024 | 2024-12-31 | 17.34M | +55841.9% |
| FY2023 | 2023-12-31 | 31K | -87.6% |
| FY2022 | 2022-12-31 | 250K | -99.5% |
| FY2021 | 2021-12-31 | 51.49M | — |
Common Stock Issued vs competitors
How MOLN compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +82.5% is the 6th highest of 8, against a peer median of +124.0%.
- Over three fiscal years its annual growth of -36.8% compares with a peer median of +219.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $109.49M USD | +6044.2% | -1.8% | — | |
| LTM Mar 2026 | $104.89M USD | +75017.8% | +219.2% | 5879.2% | |
| LTM Mar 2026 | $77.35M USD | +115.3% | — | — | |
| LTM Mar 2026 | $58.23M USD | +213.9% | +477.6% | 1837.6% | |
| LTM Mar 2026 | $20.02M USD | — | +64.2% | 108.7% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $14.61M USD | +34.0% | +589.1% | — |
| LTM Mar 2026 | $2.66M USD | -95.0% | +225.3% | 506.3% | |
| LTM Mar 2026 | $147K USD | +124.0% | -91.3% | — | |
| LTM Mar 2026 | CHF 73.01K CHF | +82.5% | -36.8% | — | |
| Peer median (excluding MOLN) | — | +124.0% | +219.2% | 1171.9% | |
Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (63.79M) | 117.85M | (61.98M) | (54.04M) | (61.65M) |
| Depreciation & Amortization | 2.57M | 2.39M | 2.42M | 2.37M | 2.14M |
| Deferred Income Tax | 2K | 0 | 0 | 2K | 2K |
| Stock-Based Compensation | 4.09M | 5.09M | 5.21M | 4.11M | 4.42M |
| Change in Working Capital | (34.67M) | (6.01M) | (6.01M) | (3.8M) | 1.16M |
| Accounts Receivables | (23.37M) | 25.26M | (933K) | (347K) | 463.2K |
| Inventory | 21.72M | (19.93M) | 0 | 0 | 0 |
| Accounts Payables | 1.66M | (5.34M) | (812K) | 524K | 62.08K |
| Other Working Capital | (34.67M) | (6.01M) | (4.27M) | (3.97M) | 630.33K |
| Other Non-Cash Items | 848K | (753K) | 1.36M | (7.88M) | 2.67M |
| Operating Cash Flow | (90.95M) | 118.57M | (59.01M) | (59.25M) | (51.26M) |
| Capital Expenditures | (1.31M) | (1.42M) | (575K) | (723K) | (714K) |
| Acquisitions (Net) | 374K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (88.88M) | (299.42M) | (277.83M) | (240.05M) | (66.28M) |
| Sales of Investments | 67.88M | 199.22M | 319.44M | 277.02M | 137.81M |
| Other Investing Activities | (304K) | 494K | 3.83M | 4.22M | 1.73M |
| Investing Cash Flow | (22.24M) | (101.12M) | 44.64M | 40.49M | 72.55M |
| Debt Repayment | (1.18M) | (1.19M) | (1.2M) | (1.21M) | (1.21M) |
| Common Stock Issued | 51.49M | 250K | 31K | 17.34M | 63K |
| Common Stock Repurchased | 0 | (631K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 267K | 250K | 31K | (1.7M) | 0 |
| Financing Cash Flow | 50.58M | (1.57M) | (1.17M) | 14.43M | (1.15M) |
| Effect of Forex Changes | 701K | 258K | (5.1M) | 894K | (1.36M) |
| Net Change in Cash | (61.91M) | 16.13M | (20.64M) | (3.44M) | 18.78M |
| Free Cash Flow | (92.26M) | 117.15M | (59.81M) | (59.97M) | (51.97M) |
Molecular Partners AG
NASDAQ:MOLN
Intrinsic Alpha fair value
Locked
Current Price
$2.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.